Last checked at 14 Apr 2022 12:24
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Exercise of Options, PDMR Dealing and Total Voting Rights
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, announces the following transactions conducted by Matthew Hall, Chief Financial Offer, which occurred on 13 April 2022. In aggregate, Matthew Hall has exercised options over 78,882 ordinary shares of 1 pence each in the Company ("Ordinary Shares") and concurrently sold 78,882 Ordinary Shares at a price of £1.26 per Ordinary Share.
Admission of the 78,882 new Ordinary Shares has been satisfied via the block listing for the Oncimmune Holdings plc 2016 Unapproved and EMI Share Option Plans.
Following these transactions, Matthew Hall holds options over a total of 779,554 Ordinary Shares, representing approximately 1.12 per cent. of the Company's issued share capital of 69,475,480.
In addition, Matthew Hall has a total interest in the Company of 11,935 Ordinary Shares, representing approximately 0.02 per cent. of the Company's issued share capital.
Total Voting rights
Immediately following Admission, the Company's issued share capital will comprise 69,475,480 Ordinary Shares. Each Ordinary Share has one voting right and no Ordinary Shares are held in treasury. Accordingly, immediately following Admission, the total number of voting rights will be 69,475,480.
From Admission, this figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Nigel Barnes
+44 (0)20 3705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue both from its portfolio of diagnostic products to detect early-stage cancer and its contract discovery and development service business whose platform delivers actionable insights into therapies to the Company's pharmaceutical and biotech partners.
Our understanding of the immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies. The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people extra time.
Oncimmune's ImmunoINSIGHTS platform enables life science organisations to optimise drug development and delivery, leading to more effectively targeted and safer treatments for patients. Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.
Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK and its ImmunoINSIGHTS service business at its discovery research centre in Dortmund, Germany. The ImmunoINSIGHTS business development team are based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.
For more information, visit www.oncimmune.com
Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them:
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Matthew Hall | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Chief Financial Officer | ||||
b)
| Initial notification /Amendment
| Initial Notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Oncimmune Holdings plc | ||||
b)
| LEI
| 213800HCYIWT6YPI1I02 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of 1 pence each | ||||
Identification code | ISIN: GB00BYQ94H38 | |||||
b)
| Nature of the transaction
| 1. Exercise of Options 2. Sale of Ordinary Shares | ||||
c)
| Price(s) and volume(s) | |||||
Price(s) | Volume(s) | |||||
1. Exercise of Options | £1.09 | 66,330 | ||||
£1.195 | 12,552 | |||||
2. Sale of Ordinary Shares | £1.26 | 78,882 | ||||
d)
| Aggregated information | 1. Exercise of Options: Aggregate volume: 78,882 Aggregate price: £1.107
| ||||
2. Sale of Ordinary Shares: N/A - single transaction | ||||||
- Aggregated volume | ||||||
- Price | ||||||
e)
| Date of the transaction | 13 April 2022 | ||||
f) | Place of the transaction | 1. Outside a trading venue 2. London Stock Exchange, AIM | ||||